Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMV

IMV (IMV) Stock Price, News & Analysis

IMV logo

About IMV Stock (NASDAQ:IMV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.49
$0.91
52-Week Range
N/A
Volume
44,800 shs
Average Volume
233,607 shs
Market Capitalization
$9.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV Stock News Headlines

Is This The Next Toyota FJ Cruiser?
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

IMV Stock Analysis - Frequently Asked Questions

IMV Inc. (NASDAQ:IMV) announced its earnings results on Thursday, November, 11th. The company reported ($1.30) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.30). The firm had revenue of $0.04 million for the quarter. IMV had a negative trailing twelve-month return on equity of 12,695.41% and a negative net margin of 11,547.42%.

IMV shares reverse split on the morning of Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMV investors own include Pfizer (PFE), Nokia Oyj (NOK), NIO (NIO), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/11/2021
Today
6/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.99 million
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330 thousand
Price / Cash Flow
N/A
Book Value
($0.69) per share
Price / Book
N/A

Miscellaneous

Free Float
11,673,000
Market Cap
$9.63 million
Optionable
Optionable
Beta
0.95
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:IMV) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners